Canagliflozin 100 mg
Sponsors
Janssen Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2HealthyHeart Failure
Phase 1
A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus
CompletedNCT01128985
Start: 2010-03-31End: 2010-07-31Updated: 2013-05-29
A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers
CompletedNCT01281579
Start: 2011-01-31End: 2011-04-30Updated: 2012-11-30
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
CompletedNCT02000700
Start: 2014-03-31End: 2016-04-30Updated: 2017-03-03
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
CompletedNCT02846506
Start: 2016-08-31End: 2016-10-31Updated: 2025-02-03
Phase 2
Phase 3
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
CompletedNCT01106651
Start: 2010-06-30End: 2013-05-31Updated: 2014-11-04
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
CompletedNCT01809327
Start: 2013-06-04End: 2014-12-02Updated: 2017-07-11
A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
CompletedNCT03170518
Start: 2017-07-21End: 2023-09-20Updated: 2025-04-25
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
CompletedNCT04252287
Start: 2020-03-10End: 2021-11-09Updated: 2025-03-30